JPWO2020084530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020084530A5 JPWO2020084530A5 JP2021521814A JP2021521814A JPWO2020084530A5 JP WO2020084530 A5 JPWO2020084530 A5 JP WO2020084530A5 JP 2021521814 A JP2021521814 A JP 2021521814A JP 2021521814 A JP2021521814 A JP 2021521814A JP WO2020084530 A5 JPWO2020084530 A5 JP WO2020084530A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amount
- composition according
- corticosteroid
- mucoadhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 137
- 239000003246 corticosteroid Substances 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 230000003232 mucoadhesive effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 9
- 239000004376 Sucralose Substances 0.000 claims description 9
- 229960004436 budesonide Drugs 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 9
- 235000019408 sucralose Nutrition 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 239000006254 rheological additive Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- 239000007979 citrate buffer Substances 0.000 claims description 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 3
- 229960002714 fluticasone Drugs 0.000 claims description 3
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749878P | 2018-10-24 | 2018-10-24 | |
| US62/749,878 | 2018-10-24 | ||
| EP19150077.6 | 2019-01-02 | ||
| EP19150077 | 2019-01-02 | ||
| PCT/IB2019/059079 WO2020084530A1 (en) | 2018-10-24 | 2019-10-23 | Mucoadhesive pharmaceutical compositions of corticosteroids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505535A JP2022505535A (ja) | 2022-01-14 |
| JPWO2020084530A5 true JPWO2020084530A5 (es) | 2022-10-31 |
| JP7479362B2 JP7479362B2 (ja) | 2024-05-08 |
Family
ID=68296606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521814A Active JP7479362B2 (ja) | 2018-10-24 | 2019-10-23 | コルチコステロイドの粘膜付着性医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210379081A1 (es) |
| EP (2) | EP4233872A3 (es) |
| JP (1) | JP7479362B2 (es) |
| KR (1) | KR20210088547A (es) |
| CN (1) | CN113271979A (es) |
| AU (1) | AU2019365253A1 (es) |
| BR (1) | BR112021007140A2 (es) |
| CA (1) | CA3116649A1 (es) |
| CL (1) | CL2021001046A1 (es) |
| CO (1) | CO2021005913A2 (es) |
| DK (1) | DK3870226T3 (es) |
| ES (1) | ES2956849T3 (es) |
| FI (1) | FI3870226T3 (es) |
| MX (1) | MX2021004537A (es) |
| PL (1) | PL3870226T3 (es) |
| WO (1) | WO2020084530A1 (es) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU778498B2 (en) * | 1999-10-22 | 2004-12-09 | Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. | Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| WO2003103691A1 (en) | 2001-06-07 | 2003-12-18 | Chiou Consulting, Inc. | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| US20030059446A1 (en) | 2001-09-18 | 2003-03-27 | Kulkarni Arun B. | Physically stable sprayable gel composition |
| US20060018937A1 (en) | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
| WO2005027939A1 (en) | 2003-08-21 | 2005-03-31 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CN101969956B (zh) * | 2007-11-13 | 2014-03-05 | 梅里蒂奇制药公司 | 皮质类固醇组合物 |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| CA2704946C (en) | 2007-11-13 | 2013-09-24 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| RU2469726C2 (ru) | 2008-05-14 | 2012-12-20 | Отономи, Инк. | Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней |
| JP2012528889A (ja) | 2009-06-05 | 2012-11-15 | アーシエックス セラピューティックス， インコーポレイテッド | フルチカゾンの眼科処方物および使用方法 |
| US20120164080A1 (en) | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
| EP3181120A1 (en) | 2012-11-09 | 2017-06-21 | Scidose LLC | Enema composition for treatment of ulcerative colitis having long term stability |
| US9901544B2 (en) | 2014-05-01 | 2018-02-27 | Integral Biosystems Llc | Membrane-adherent self-assembled system for treatment of ocular disorders |
| JP6814162B2 (ja) | 2015-05-04 | 2021-01-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 結腸に治療剤を送達するための組成物及び方法 |
-
2019
- 2019-10-23 DK DK19790866.8T patent/DK3870226T3/da active
- 2019-10-23 CA CA3116649A patent/CA3116649A1/en active Pending
- 2019-10-23 FI FIEP19790866.8T patent/FI3870226T3/fi active
- 2019-10-23 MX MX2021004537A patent/MX2021004537A/es unknown
- 2019-10-23 BR BR112021007140-7A patent/BR112021007140A2/pt unknown
- 2019-10-23 WO PCT/IB2019/059079 patent/WO2020084530A1/en active Application Filing
- 2019-10-23 KR KR1020217011830A patent/KR20210088547A/ko unknown
- 2019-10-23 EP EP23181722.2A patent/EP4233872A3/en active Pending
- 2019-10-23 AU AU2019365253A patent/AU2019365253A1/en active Pending
- 2019-10-23 CN CN201980084843.5A patent/CN113271979A/zh active Pending
- 2019-10-23 JP JP2021521814A patent/JP7479362B2/ja active Active
- 2019-10-23 ES ES19790866T patent/ES2956849T3/es active Active
- 2019-10-23 EP EP19790866.8A patent/EP3870226B1/en active Active
- 2019-10-23 US US17/288,385 patent/US20210379081A1/en active Pending
- 2019-10-23 PL PL19790866.8T patent/PL3870226T3/pl unknown
-
2021
- 2021-04-23 CL CL2021001046A patent/CL2021001046A1/es unknown
- 2021-05-05 CO CONC2021/0005913A patent/CO2021005913A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101546596B1 (ko) | 베포타스틴 조성물 | |
| JP2010502612A5 (es) | ||
| US8663659B2 (en) | Orally administrable films | |
| JP2023002662A5 (es) | ||
| BRPI0715364A2 (pt) | mÉtodos para tratar e prevenir mucosite | |
| KR20150011807A (ko) | 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물 | |
| RU2015102575A (ru) | Жидкие композиции рацекадотрила | |
| JP2019534265A5 (ja) | 医薬組成物およびその投与方法 | |
| JP2023166406A5 (es) | ||
| JP2015500285A5 (es) | ||
| TWI351960B (en) | Multiphase product for contraception based on a na | |
| JP3691487B2 (ja) | 炎症性気道疾患の予防・治療剤 | |
| JP2022173567A (ja) | 注腸剤 | |
| EP2328553B1 (en) | Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract | |
| JPWO2020084530A5 (es) | ||
| JP5032003B2 (ja) | 口腔粘膜用の鎮痛・抗炎症トローチ剤 | |
| CN112770765B (zh) | 用于预防和/或治疗泌尿生殖器粘膜的组合物 | |
| EA025203B1 (ru) | Фармацевтический состав для назального применения, содержащий флутиказон | |
| ITMI20101908A1 (it) | Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali | |
| Dickson | Radiotherapy of lethal mid-line granuloma | |
| FI3870226T3 (fi) | Mukoadhesiivisia kortikosteroidien farmaseuttisia koostumuksia | |
| JP2006070027A (ja) | 口腔粘膜投与剤 | |
| JP5930332B2 (ja) | アンブロキソールを含む噴霧可能な組成物の使用 | |
| JP4783887B2 (ja) | 心筋組織の障害を抑制するための医薬組成物 | |
| WO2021256547A1 (ja) | ＳＡＲＳ－ＣｏＶ－２感染症の治療、予防または緩和用組成物 |